Experiences with
Chlorambucil110 public posts
Median PFS for FCR treated CLL patients with IGHV-M was 14.6 years vs 4.2 years for patients with IGHV-UM. V+O and I+R look to be superior
Prior to the advent of targeted therapies, we only had chemoimmunotherapy treatments, typically BR (bendamustine+rituximab) or a very old drug chlorambucil to offer to most patients needing treatment.
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
[/i]
[i]However, only trends toward improvement in overall survival have been seen as compared with chlorambucil and obinutuzumab. These approaches are based on the principle that “one size fits all,” and therapy is not individualized on the basis of response.
Want to take advantage of all our features? Just log in!
or
Optimal Treatment Combinations in the Management of CLL/SLL Jeff Sharman, MD Provided by Clinical Care Options, LLC
In the randomized phase III CLL11 study, either obinutuzumab or rituximab was combined with chlorambucil compared with chlorambucil alone for patients with previously untreated CLL and coexisting conditions.
Concise summary of the treatment history of CLL from the 1950s to the present, by Dr Bruce Cheson, contributor to the iwCLL and much more
I knew Chlorambucil use for CLL dated back to the 1950's but I hadn't appreciated that was also the case for cyclophosphamide, (the 'C' in FCR).
Relapsed CLL: New Approaches Prolong Survival
Study participants were treated with six cycles of either venetoclax-obinutuzumab (VO) or chlorambucil-obinutuzumab (CO); the 4-year PFS was 74% vs. 35.4% (P < .0001) respectively.
Frontline treatment of Chronic Lymphocytic Leukemia (CLL/SLL) in 2021
Until recently, chemoimmunotherapy regimens such as fludarabine, cyclophosphamide, and rituximab (FCR), bendamustine and rituximab, and chlorambucil and obinutuzumab were considered standard first-line therapy for patients with CLL.
From the CLL14 Study: Venetoclax Plus Obinutuzumab Prolongs Progression Free Survival, Not Overall Survival , in CLL
plus obinutuzumab or chlorambucil plus obinutuzumab.
Frontline Ibrutinib/Venetoclax Elicits Durable Responses in CLL With Undetectable MRD
Fixed duration ibrutinib and venetoclax (I+V) versus chlorambucil plus obinutuzumab (CLB+O) for first-line (1L) chronic lymphocytic leukemia (CLL): primary analysis of the phase 3 GLOW study.
Long-Term Data Showcase the Clinical Utility of Fixed-Duration Venetoclax/Obinutuzumab in Treatment-Naïve CLL
Additionally, undetectable MRD remissions were found to be deeper and more sustained with venetoclax/obinutuzumab vs chlorambucil/obinutuzumab in this patient population.